Hormone receptors as a marker of poor survival in epithelial ovarian cancer (Q85478789)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

title

Hormone receptors as a marker of poor survival in epithelial ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

1

Michel van Kruchten

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

8

Geke Hospers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

6

Hetty Timmer-Bosscha

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Pauline van der Marel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

Linda de Munck

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

Harry Hollema

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

Henriette Arts

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

Anna Reyners

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

publication date

24 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

volume

138

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

634-639

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

A phase II study of flutamide in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

REporting recommendations for tumor MARKer prognostic studies (REMARK).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas:

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Estrogen Receptor Subtypes in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Expression of androgen receptors in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2015.06.032

10.1016/J.YGYNO.2015.06.032

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26115976 AND SRC:MED&resulttype=core&format=json

18 February 2020

1 reference